Inactive Instrument

Profound Medical Corp Share Price Toronto S.E.

Equities

PRN

CA74319B1067

Advanced Medical Equipment & Technology

End-of-day quote Toronto S.E.
- CAD - Intraday chart for Profound Medical Corp
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 15.5M 11.38M 948M Sales 2025 * 41.51M 30.48M 2.54B Capitalization 273M 201M 16.72B
Net income 2024 * -40M -29.37M -2.45B Net income 2025 * -31M -22.76M -1.9B EV / Sales 2024 * 17.6 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 6.58 x
P/E ratio 2024 *
-7.01 x
P/E ratio 2025 *
-7.58 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 91.29%
More Fundamentals * Assessed data
Transcript : Profound Medical Corp. - Shareholder/Analyst Call
Sector Update: Health Care Stocks Steady Premarket Tuesday MT
Profound Medical Receives FDA Approval for AI-Powered Prostate Disease Device --Shares Advance Pre-Bell MT
Profound Medical Receives U.S. FDA Clearance for "Contouring Assistant" AI Module MT
Profound Medical Brief: Says Received U.S. FDA 510(k) Clearance for 'Contouring Assistant' AI Module that Enables Creation of an Automated TULSA Treatment Plan MT
Profound Medical Receives U.S. FDA 510(K) Clearance for Contour Assistant AI Module That Enables Creation of an Automated Tulsa Treatment Plan CI
Profound Reports a Narrower First-Quarter Loss; Provides 2024 Revenue Guidance MT
Transcript : Profound Medical Corp., Q1 2024 Earnings Call, May 09, 2024
Profound Medical Brief: Expects total revenue for FY24 to be in the range of US$11.0-$12.0 million, which represents 53% to 67% growth compared to its prior year revenue MT
Profound Medical Brief: Recorded Q1 revenue of approximately $1.91 million, with $1.48 million from recurring revenue; Issues Full-Year 2024 Revenue Guidance MT
Profound Medical Corp. Provides Earnings Guidance for Full-Year 2024 CI
Profound Medical Says Clinical Evidence Points to Potential of Its TULSA Procedure as a Treatment for Prostate Cancer MT
Profound Medical Brief: Adds Clinical evidence Continues to highlight TULSA's "Ability to treat an unrivalled variety of patients with localized prostate cancer and/or BPH" MT
Profound Medical Brief: Says "Growing Body of Clinical Evidence" Points to Potential of Its TULSA Procedure "Becoming a Mainstream Treatment Modality Across the Entire Prostate Disease Spectrum" MT
Transcript : Profound Medical Corp. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 11:15 AM
More news

Latest transcript on Profound Medical Corp

Managers TitleAgeSince
Chief Executive Officer 69 04/15/04
Director of Finance/CFO 56 01/15/01
Chief Operating Officer 42 07/11/07
Members of the board TitleAgeSince
Director/Board Member 77 14/18/14
Director/Board Member 67 14/18/14
Director/Board Member - 03/21/03
More insiders
Profound Medical Corp. is a Canada-based commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), robotically driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while protecting the urethra and rectum. TULSA-PRO has the potential to be a flexible technology in customizable prostate ablation, including intermediate stage cancer, localized radio-recurrent cancer, retention and hematuria palliation in locally advanced prostate cancer and the transition zone in large volume benign prostatic hyperplasia. It is also commercializing Sonalleve, which is a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW